Due to the very promising results from the global CodeBreaK 101 trial, a new multicenter, randomized, open-label, phase 3 study (CodeBreaK 202) of sotorasib plus carboplatin and pemetrexed as frontline therapy of PD-L1 negative, KRAS G12C-mutant advanced NSCLC has been recently initiated by Amgen and is currently recruiting patients (enrollment start date: November 26, 2023; estimated study completion date: March 1, 2031) (45). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.